In particular, previous studies reported that PARP inhibitors enhanced the anti-tumor effects of cisplatin, especially in breast cancer [43,44], as well as of temozolomide in Ewing’s sarcoma [45] or camptothecin in childhood neuroblastoma [46]. This evidence concerns the gene PARP1 and neuroblastoma.